T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer

Real-world studies have suggested decreased trastuzumab emtansine (T-DM1) effectiveness in patients with metastatic breast cancer (mBC) who received prior trastuzumab plus pertuzumab (H + P). However, these studies may have been biased toward pertuzumab-experienced patients with more aggressive dise...

Full description

Bibliographic Details
Main Authors: Thibaut Sanglier, Alessandra Fabi, Carlos Flores, Evelyn M. Flahavan, Claudia Pena-Murillo, Anne-Marie Meyer, Filippo Montemurro
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
trastuzumab emtansine
HER2-positive metastatic breast cancer
selection bias
real-world data
trastuzumab
pertuzumab
Online Access:https://www.mdpi.com/2072-6694/14/10/2468

Internet

https://www.mdpi.com/2072-6694/14/10/2468

Similar Items